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Novel wrapped liposomes comprised of polyanion drug and cationic lipid complexes wrapped with neutral lipids were prepared using an
efficient, innovative procedure. In this study, dextran fluorescein anionic (DFA) was used as an example of a polyanionic compound. During the
process, neutral lipids accumulated around the complexes and eventually covered the complexes. The resulting liposomes were 120–140 nm in
diameter and the encapsulation efficiency was up to 90%. In fetal bovine serum, DFA/cationic lipid complexes degraded rapidly but the wrapped
liposomes were considerably more stable. Following intravenous administration to rats, DFA/cationic lipid complexes were rapidly eliminated
whereas the wrapped liposomes exhibited a much longer blood half-life. These data suggest that DFA is located on the surface of the complexes,
but DFA is present inside the wrapped liposomes. The drug-delivery properties of the wrapped liposomes established in the present study suggests
that formulations based on this technology could offer important advantages for the administration of many types of drug including antisense
oligonucleotides, plasmids and siRNAs which may therefore lead to improved therapeutic effectiveness of this range of drugs. The method of
preparation of the wrapped liposomes is so simple that it should be straightforward to adapt to a manufacturing scale.
© 2006 Elsevier B.V. All rights reserved.Keywords: Liposome; Cationic lipid; Drug delivery; Formulation; DOTAP; PEG1. Introduction
Liposomes are widely used as carriers for a variety of
drugs [1,2]. In general, liposomes protect the drug from
metabolism and inactivation in the plasma [3]. Encapsulation
into polyethylene glycol (PEG) liposomes increases the
efficacy and decreases the side effects of the drugs because
the drugs are delivered preferentially to the site of action due
to the enhanced permeability and retention effect [4]. A large
number of drugs with weak basic or acidic characteristics can
be actively concentrated in liposomes in response to a
transmembrane pH gradient [5] or ammonium sulfate gradient⁎ Corresponding author. Tel.: +81 55 989 2018; fax: +81 55 989 2089.
E-mail address: masahiro.yamauchi@kyowa.co.jp (M. Yamauchi).
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doi:10.1016/j.bbamem.2006.01.013[6]. However, these methods are restricted to low molecular
weight drugs. High molecular weight drugs such as peptides,
proteins, antisense oligonucleotides (ODNs), plasmids and
siRNAs cannot be efficiently loaded into liposomes using a
pH gradient [7]. It may be feasible to incorporate such high
molecular weight drugs into liposomes comprised of neutral
lipids but a low encapsulation efficiency would limit the
practical application of this approach [8,9]. An alternative
strategy would be to introduce high molecular weight drugs
into cationic liposomes that should result in high encapsula-
tion efficiencies and the presence of cationic lipids would
facilitate uptake by cells [9–11]. However, cationic liposomes
are very unstable in blood and are rapidly eliminated in vivo
after intravenous administration [9,12]. Consequently, cationic
liposomes cannot deliver nucleic acids to specific target sites
in the body, especially to solid tumors. Furthermore, cationic
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systemic administration of cationic liposomes [13,14].
Recently, coated cationic liposomes (CCL) and stabilized
antisense lipid particles (SALP) described by Stuart et al.
[15,16] and Semple et al. [17,18], respectively, were reported
to overcome the problems described above. Both these
liposomal formulations have high encapsulation efficiencies,
good stability in blood and long duration after intravenous
administration. Moreover, they have been studying in vivo
activities of their liposomes.
The purpose of this study was to identify alternative
liposomal formulations of high molecular weight compounds
that are stable in blood and to develop a novel method of
preparing such formulations that achieve a high encapsulation
efficiency (i.e., different from CCL and SALP). We
recognized that the presence of multiple charged groups in
nucleic acids and peptides might present challenges to
producing an effective formulation; therefore, our investiga-
tions were conducted with dextran fluorescein anionic (DFA)
as a model multiple-charged compound. The strategy was to
produce complexes of DFA with cationic lipids and to wrap
these complexes with neutral lipids.2. Materials and methods
2.1. Materials
Dextran, fluorescein, 3000 MW, anionic (DFA) was purchased from
Molecular Probes (Eugene, OR). Egg phosphatidylcholine (EPC) was purchased
from Nippon Oil and Fat (Tokyo, Japan). 1,2-Dioleoyl-3-trimethylammonium
propane (DOTAP) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(Polyethylene glycol)-2000] (PEG-DSPE) were purchased from
Avanti Polar Lipids (Alabaster, AL). Fetal bovine serum (FBS) was purchased
from GIBCO BRL (Grand Island, NY). Nuclepore polycarbonate filters were
purchased from Corning (Acton, MA). Sepharose CL-4B was purchased from
Amersham-Pharmacia Biotech (Uppsala, Sweden). All other chemicals and
solvents were of analytical grade quality.
2.2. Animals
Male Crl:CD(SD) rats, 7 to 8 weeks of age (Charles River, Japan, Inc.,
Yokohama, Japan, 200 to 300 g at the start of the experiments), were housed for
about one week under controlled conditions with free access to food and water
before use. The Welfare Committee for Experimental Animals in our institute
approved all the experiments performed in the study.
2.3. Preparation of DFA/DOTAP/PEG–DSPE complexes
A mixture of 10 mg DFA, 60 mg DOTAP and 24 mg PEG–DSPE (DFA/
DOTAP/PEG–DSPE, 1/26/2.6, mol/mol/mol) were hydrated in 3 mL distilled
water and extruded 20 times through two stacked Nuclepore polycarbonate
membrane filters with pore sizes of 0.4 and 0.1 μm. The resultant complexes
were diluted with two volumes of water and centrifuged in an ultracentrifuge
(Optima™ XL-A, Beckman, Fullerton, CA) for 1 h at approximately
110,000×g. The supernatant containing uncomplexed DFA was removed and
the pellet containing the complexes was resuspended in water to provide a
preparation containing 30 mg/mL total lipids. The particle sizes and Zeta
potentials of the resultant complexes were measured by dynamic light scattering
(Zetasizer Nano-ZS, Malvern Instruments, Herrenberg, Germany). Average
diameters were evaluated as a Z-average using monomodal method (a cumulant
analysis). The volume-based distributions were obtained by Nano-ZS in the
Gaussian-fit mode.2.4. Preparation of wrapped liposomes
Aliquots (0.75 mL) of the complexes obtained after sizing were diluted with
1 mL ethanol. An ethanolic solution of EPC and PEG–DSPE (0.25 mL of a
solution containing EPC 240 mg/mL and PEG–DSPE 50 mg/mL, EPC/PEG–
DSPE, 17.3/1, mol/mol) was added to the complexes. At this stage, the
proportion of ethanol in the mixture was 62.5% (v/v), and the concentrations of
DFA, DOTAP and PEG–DSPE in complexes were 1.25, 7.5 and 3 mg/mL
(DFA/DOTAP/PEG–DSPE, 1/26/2.6, mol/mol/mol), respectively, and the
concentrations of additional EPC and PEG–DSPE were 30 and 6.25 mg/mL,
respectively. Distilled water (23 mL) was slowly added whilst stirring the
mixture continuously. The suspension was centrifuged for 1 h at approximately
110,000×g. The supernatant was discarded thereby eliminating ethanol
completely. Less than 10% DFA was detected in the supernatant. The pellet
was resuspended in phosphate buffered saline (PBS; pH 7.4) to provide a
preparation containing 30 mg/mL total lipids. The particle size of the resultant
wrapped liposomes was measured by dynamic light scattering and the content of
EPC was determined using the phosphorus assay (Wako, Tokyo, Japan).
As a control, wrapped liposomes without complexes were prepared as
follows: An aliquot (0.25 mL) of an ethanolic solution of EPC and PEG–DSPE
(EPC 240 mg/PEG–DSPE 50 mg/mL, EPC/PEG–DSPE, 17.3/1, mol/mol) was
added to aqueous ethanol (57.1%; 1.75 mL). Distilled water (23 mL) was slowly
added to this suspension whilst stirring. The suspension was centrifuged for 1
h at approximately 110,000×g. The supernatant was removed and the pellet
resuspended in PBS to provide a preparation containing 30 mg/mL total lipids.
2.5. Solubility in aqueous ethanol
The solubility of free DFA and various preparations in aqueous ethanol
was determined by monitoring turbidity at 600 nm (U-3210, Hitachi, Tokyo,
Japan). Compounds or preparations were added to water containing varying
amounts of ethanol and these samples were stirred vigorously for about 1 min
at room temperature. The amounts of compounds added to aqueous ethanol
were as follows: free DFA 1.25 mg/mL: DOTAP and PEG–DSPE in DOTAP/
PEG–DSPE liposomes were 7.5 and 3 mg/mL (DOTAP/PEG–DSPE, 26/2.6,
mol/mol), respectively; DFA, DOTAP and PEG–DSPE in DFA/DOTAP/
PEG–DSPE complexes were 1.25, 7.5 and 3 mg/mL (DFA/DOTAP/PEG–
DSPE, 1/26/2.6, mol/mol/mol), respectively; EPC and PEG–DSPE in EPC/
PEG–DSPE were 30 and 6.25 mg/mL (EPC/PEG–DSPE, 17.3/1, mol/mol),
respectively.
2.6. Microscopy
Negative-stain electron microscopy was performed using the method of
Magin and Weinstein [19] to assist examination of the morphology of the
liposomes. Aliquots of wrapped liposomes, naked (unwrapped) complexes and
wrapped liposomes in the absence of complexes were added to 1% aqueous
solution of ammonium molybdate (adjusted to pH 7.3 using ammonia) to
provide solutions containing 0.5 mg/mL total lipids. Several drops of each
sample were placed on separate collodion-coated copper grids of mesh size 400
(Nisshin EM Co., Tokyo, Japan). After 1 min, excess water was absorbed onto
filter paper. The grids were air dried and then examined under a H-7000 electron
microscope (Hitachi, Tokyo, Japan) at 75 kV voltage.
2.7. Effect of NaCl
Changes in turbidity caused by the addition of NaCl solution were monitored
by measuring the absorbance at 600 nm before and after addition of 0.1 volumes
of NaCl solution to samples of wrapped liposomes and complexes [20]. The
final concentration of NaCl in this turbidity test was 0.9 w/v%. The particle sizes
of wrapped liposomes and complexes before and after addition of NaCl solution
were also measured by dynamic light scattering.
2.8. Stability in FBS
In vitro release experiments were carried out in test tubes by diluting samples
1:99 (v/v) with 100% FBS. The concentration of total lipids in each mixture was
92 M. Yamauchi et al. / Biochimica et Biophysica Acta 1758 (2006) 90–970.3 mg/mL. The mixtures were incubated at 37 °C and aliquots were removed at
different times up to 6 h for determination of liposomal and released DFA.
Liposomal DFA was separated from released DFA by a Sepharose CL-4B
column (1.0×20 cm) equilibrated with PBS (pH 7.4) at 25 °C. An aliquot of
each mixture was applied onto the column, which was eluted with PBS at
approximately 0.5 mL/min. For analysis of DFA in the eluent, samples were
diluted with 9 volumes of 1% triton X-100 solution and these solutions were
analyzed fluorometrically using a multiwell fluorescence plate reader, Cyto-
fluor™ II (PE Biosystems, Foster city, CA) with excitation and emission
monochrometers set at 485 nm and 530 nm, respectively. Measurement of DFA
in the first and second eluant provided quantification of liposomal and released
DFA. The retention of DFA in liposomes was calculated as a percentage of total
DFA applied onto the column.
2.9. Rat PK
Aliquots of naked complexes and wrapped liposomes were diluted to
provide solutions containing 5 mg/mL total lipids. Free DFA was dissolved at
0.2 mg/mL in PBS. Rats were fixed in a dorsal position under urethane
anesthesia (1 g/kg, i.p.) then samples of complexes, wrapped liposomes and free
DFAwere administered rapidly to separate groups of 3 rats via the femoral vein
at a volume of 2 mL/kg. The dose of total lipids was 10 mg/kg. For the analysis
of the plasma concentrations of DFA, approximately 0.3 mL blood was
withdrawn at 1, 3, 10, 30, 60 and 180 min after dosing from the jugular vein
using heparinized syringes; the blood samples were centrifuged for 5 min at
10,000×g at 4 °C and the plasma was removed. The DFA concentration in each
plasma sample was determined by monitoring fluorescence (see Section 2.8).
The % of the injected dose of DFA present in the plasma compartment was
calculated assuming that the plasma volume of a 250 g rat was 7.8 mL [21]. The
elimination half-lives (t1/2), the areas under the plasma concentration–time
curves (AUC0–3 h), the mean residence times (MRT) in rats were calculated from
the plasma concentration–time curves after intravenous injection by a non-
compartment model using the software package WinNonlinTM Professional
Ver.4.1 (Pharsight Co., Mountain View, CA).3. Results
3.1. Solubility in ethanol
The degree of turbidity, which provides an indication of
solubility, of free DFA and a range of lipid preparations in water
containing varying concentrations of ethanol is shown in Fig. 1.
The data revealed that DFAwas dissolved completely in 0–70%Fig. 1. The solubility of each sample in aqueous ethanol at 25 °C was measured.
DOTAP/PEG–DSPE (7.5 mg/3 mg/mL, DOTAP/PEG–DSPE, 26/2.6, mol/mol)
(□), DFA/DOTAP/PEG–DSPE (1.25 mg/7.5 mg/3 mg/mL, DFA/DOTAP/
PEG–DSPE, 1/26/2.6, mol/mol/mol) (•), DFA (1.25 mg/mL) (▴) and EPC/
PEG–DSPE (30 mg/6.25 mg/mL, EPC/PEG–DSPE, 17.3/1, mol/mol) (○).ethanol solution but that the compound came out of solution at
the highest concentrations of ethanol. EPC/PEG–DSPE only
dissolved when the ethanol concentration was over 60%.
DOTAP/PEG–DSPE was slightly insoluble in 0–30% ethanol
but was completely dissolved when the proportion of ethanol
was greater than 30%. However, DFA/DOTAP/PEG–DSPE
complexes did not dissolve completely in aqueous ethanol at
any concentration of ethanol.
3.2. Preparation of complexes
Complexes were prepared efficiently by the procedure
described in “Materials and methods”. The representative
particle size and polydispersity of complexes were 104 nm
and 0.12, respectively. The representative distribution of
complexes is shown in Fig. 2A. Most of the DFA will be
complexed to the outer surface of the DOTAP/ PEG–DSPE
liposome but some DFA may also be encapsulated inside the
liposomes because DFA was mixed with DOTAP and PEG–
DSPE before the vesicles were formed. Small complexes (104
nm, polydispersity 0.12) were formed in water whereas large
complexes (1417 nm, polydispersity 0.28) were produced in
PBS, probably because charged ions associated electrostatically
with complexes. The complexes with PEG–DSPE are likely to
more stable than complexes composed of DFA and DOTAP,
because interaction between complexes would cause aggrega-
tion and precipitation in the absence of PEG–DSPE. The
preparation of wrapped liposomes was explored using com-
plexes of PEG–DSPE that were formed in water.
3.3. Preparation of wrapped liposomes
In the absence and presence of PEG–DSPE in wrapping
lipids (EPC/PEG–DSPE), the wrapped liposomes were formed.
As PEG–DSPE is essential for leading to increased circulation
times and enhanced localization of the wrapped liposomes in
diseased tissues, wrapping lipids composed of EPC and PEG–
DSPE were selected. The procedures described in Materials and
methods enabled efficient formulation of the complexes
wrapped with neutral lipids; the formulation process achieved
encapsulation efficiencies of up to 90%. The representative
particle size and polydispersity of the wrapped liposomes were
122 nm and 0.07, respectively. The representative distribution
of the wrapped liposomes is shown in Fig. 2B.
3.4. Microscopy observation
Wrapped liposomes, naked complexes and wrapped lipo-
somes in the absence of complexes were examined using
transmission electron microscopy. However, attempts to
observe the complexes failed because the complexes rapidly
aggregated when ammonium molybdate was added. Micro-
graphs of the wrapped liposomes revealed small vesicles in the
outer membrane and the morphology of these vesicles was
different from the morphology of the outer membrane of the
wrapped liposomes (Fig. 3A). Micrographs of wrapped
liposomes not containing complexes did not show small
Fig. 3. Negative stain electron micrographs of wrapped liposomes (A) and
liposomes without DFA/DOTAP/PEG–DSPE complexes (B). Arrows indicate
the vesicles containing particles.
Fig. 2. Size distributions of the complexes (A) and the wrapped liposomes (B) as
determined by dynamic light scattering. The size distributions were shown as the
volume-based distributions obtained by Nano-ZS in the Gaussian-fit mode.
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vesicles observed (Fig. 3A) are likely to be DFA/DOTAP/
PEG–DSPE complexes. The wrapped liposomes with no
complexes were larger in size than those containing complexes
(Fig. 3A). In case of the presence of the complexes, the neutral
lipids accumulated around the complexes and deposited. In
case of absence of the complexes, however, there was no target
object which the neutral lipids should accumulate around.
Absence of the complexes may result in the formation of larger
liposomes. Using the dynamic light-scattering measurement,
the particle sizes (with polydispersity in parentheses) of the
complexes, the wrapped liposomes in the absence and presence
of the complexes were 105 nm (0.11), 187 nm (0.09) and 132
nm (0.09), respectively. The thickness of the anhydrous bilayer
is approximately 4 nm [22]. Microscopic examination
suggested that the thickness of the inner aqueous layer of the
wrapped liposomes was approximately 5–20 nm. Thus, the
combined increase in thickness of the anhydrous bilayer and
inner aqueous layer would imply approximately 18–48 nm
increase in particle size from the complexes to the wrapped
liposomes, which is in agreement with the observed approx-
imate 20–30 nm increase in size. The size of the complexes
was slightly smaller than 105 nm when observed by
microscopy. The particle size of the complexes may decrease
during the preparation of the wrapped liposomes. The
structural features of the wrapped liposomes are currently
being investigated further.3.5. Turbidity changes on addition of NaCl
Turbidity increased immediately after addition of NaCl to
complexes (Fig. 4A). However, turbidity was unaffected when
NaCl was added to the wrapped liposomes (Fig. 4B). The
observed changes in turbidity were consistent with the particle
sizes determined by dynamic light scattering. The particle sizes
of the complexes were 124 nm (polydispersity 0.14) and 480
nm (polydispersity 0.32) before and after the addition of NaCl,
respectively, whereas the particle sizes of the wrapped
liposomes were 145 nm (polydispersity 0.09) and 164 nm
(polydispersity 0.27) before and after the addition of NaCl. The
interpretation of these data is that the naked complexes had a
charged surface and therefore were affected by the presence of
NaCl but that the wrapped liposomes had a neutral surface and
were consequently less affected by addition of NaCl. The
minimal effect on the particle size of the wrapped liposomes
produced by the addition of NaCl implies that neutral lipids
covered the complexes extensively. On the other hand, when
Zeta potentials were measured directly in NaCl solution, there
was no large difference between the Zeta potentials of the
complexes (5.1 mV) and the wrapped liposomes (0.1 mV)
though the Zeta potentials of the complexes were slightly larger
than those of the wrapped liposomes. Thus, the presence of PEG
may shield the charges on the surface.
3.6. Stability in FBS
Rapid release of DFA was observed when naked
complexes were incubated in FBS (Fig. 5). Electrostatic
Fig. 6. Plasma levels of DFA following intravenous administration to rats of
wrapped liposomes (•), naked complexes (○) and free DFA (▴). Free DFAwas
administered at a dose of 0.4 mg/kg. Wrapped liposomes and complexes were
administered at approximate total lipid doses of 10 mg/kg. Data represent the
mean±S.D. from three animals.
Fig. 4. Change in the relative turbidity of wrapped liposomes (A) and naked
complexes (B) following addition of NaCl solution at 25 °C.
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with DFA and DOTAP probably contributed to the rapid
release of DFA and DOTAP from complexes. On the other
hand, slow release of DFA was observed when the wrapped
liposomes were incubated in FBS (Fig. 5), thereby demon-
strating the stability afforded by covering the complexes with
neutral lipids. Consequently, we anticipate that wrapped
liposomes are capable of localizing and releasing their
content at the site of action. Some DFA was released from
the wrapped liposomes immediately after addition to FBS,Fig. 5. In vitro retention of DFA in wrapped liposomes (•) and naked
complexes (○). Retention was measured after incubation in FBS at 37 °C. [Total
Lipids]=0.3 mg/mL. Data represent the mean±S.D. from three experiments.which suggests that some complexes may not have been
completely covered by neutral lipids.
3.7. Rat PK
After bolus intravenous administration of DFA solution and
complexes to rats, DFAwas eliminated rapidly from blood; the
blood level of DFAwas 31.0% and 24.8% of the injected dose at
1 min after injection of DFA solution and complexes,
respectively, and 0.3% and 0.3% at 180 min (Fig. 6). The
plasma PK of the complexes was similar to that reported
previously [12]. After intravenous administration of the
wrapped liposomes, the blood level of DFA was much higher
than that after administration of DFA solution and naked
complexes; the blood level of DFA was 57.0% of the injected
dose at 1 min after injection and 23.6% at 180 min (Fig. 6). The
half-life, AUC0–3 h and MRT of encapsulated DFA in wrapped
liposomes (12.9 h, 3.31 h·μg/mL, 18.3 h, respectively) were
significantly greater than the respective pharmacokinetic
parameters observed for naked DFA (0.76 h, 0.73 h·μg/mL,
0.61 h) and for DFA in the complexes (0.79 h, 0.80 h·μg/mL,
0.71 h) suggesting that DFA in wrapped liposomes was cleared
more slowly from the circulation than naked DFA and DFA in
the complexes. Thus, the wrapping of DFA/DOTAP/PEG–
DSPE complexes with EPC/PEG–DSPE was effective at
extending the half-life of DFA. In fact, the wrapped liposomes
provided extended circulation times comparable to those
achieved with conventional stealth liposomes such as Doxil
[23].
4. Discussion
In this study, we developed novel liposomes that we have
termed “wrapped liposomes”, which have a small diameter and
high encapsulation efficiency. The formulation approach was
evaluated using polyionic DFA as a test compound. The
wrapped liposomes were more stable in FBS than naked DFA/
cationic lipids complexes. Also, higher concentrations of total
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administration of wrapped liposomes compared to levels
achieved after administration of naked complexes.
The preparation method involved the formation of DFA/
cationic lipids complexes that were subsequently wrapped with
neutral lipids using differences of solubility in aqueous ethanol.
The solubility of cationic lipids in aqueous ethanol was
decreased by complexation with DFA. DOTAP/ PEG–DSPE
liposomes were soluble in aqueous ethanol (30–100% v/v).
However, DFA/DOTAP/PEG–DSPE complexes were insoluble
in aqueous ethanol (0–100% v/v) suggesting that the surfaces of
DOTAP/PEG–DSPE liposomes were homogenously covered
with DFA. On the other hand, EPC/PEG–DSPE was soluble in
aqueous ethanol when the proportion of ethanol was over 50%
(v/v). Therefore, in 62.5% ethanol, the complexes were
insoluble and neutral lipids were dissolved (Fig. 7). Under the
condition, the optical density of the aqueous ethanol solution
prepared with the complexes increased more than twice, which
could suggest the formation of aggregates. However, the
particle size of the resultant wrapped liposomes was 122 nm,
as recorded in Section 3.3, implying that aggregates were not
present although it is possible that aggregation was a reversible
process. It was assumed that when the ratio of ethanol was
decreased by addition of distilled water, the neutral lipids
gradually deposited around the complexes and finally the
complexes were covered with neutral lipids. It was confirmed
that the complexes were covered with neutral lipids by
microscopic examination, turbidity changes after the addition
of NaCl, stability in FBS and PK in rats following intravenous
administration. All of the data supported the proposition that theFig. 7. Schematic showing the steps and hypothesized intermediate structures invo
complexes were formed in water. (B) Ethanol was added and then EPC/PEG–DSPE w
water (62.5/37.5, v/v). (C) Water was added and EPC/PEG–DSPE precipitated aroucomplexes were covered with neutral lipids and that DFA was
present inside the liposomes and not on the surface of
liposomes.
The presence of PEG–DSPE in the complexes and wrapping
lipids (EPC/PEG–DSPE) might make wrapping lipids accu-
mulate around the complexes more efficiently and orderly.
Aqueous two-phase partitioning occurs when PEG is mixed
with dextran in water. When PEG liposomes were added to this
two phase system consisting of PEG and dextran, PEG
liposomes partitioned into the PEG phase [24], which may be
attributable to the interaction of PEG liposomes with other PEG
molecules. The initial step in the process was presumed to
involve the accumulation of PEG–DSPE around the complexes
caused by this PEG–PEG interaction between PEG–DSPE in
the complexes and PEG–DSPE used for wrapping. Secondly,
EPC accumulated around the complexes presumably due to the
hydrophobic interaction between the acyl chains of EPC and the
acyl chains of PEG–DSPE. The mechanisms involved in the
formation of the wrapped liposomes are currently being
investigated further.
Attempts have been made to develop several ODNs, such as
ISIS-3521 and G3139, as anticancer drugs [25,26]. However,
some development projects were terminated in Phase III clinical
trials because dosing failed to achieve efficacious anti-tumor
responses in humans [27,28]. The main problem was likely to
be poor delivery of ODNs to the target site. Encapsulation of
ODNs in liposomes was proposed by Yu et al. [8] as a possible
method of resolving the problem.
When ODNs are encapsulated into neutral liposomes
covered with PEG derivatives, the liposomes are not rapidlylved in the preparation of wrapped liposomes. (A) DFA/DOTAP/PEG–DSPE
as added. Complexes were insoluble and EPC/PEG–DSPEwas soluble in EtOH/
nd the complexes to produce wrapped liposomes.
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plasma; consequently these formulations can provide long
circulation half-lives [8]. However, the encapsulation efficiency
of neutral liposomes is low (25–30%) which is a disadvantage
for practical applications [8]. On the other hand, cationic
liposomes are capable of high encapsulation efficiencies and
offer enhanced intracellular delivery [9,10]. However, the
negatively charged ODNs are only adsorbed on the surface of
the positively charged liposomes by electrostatic interaction
and, therefore, cationic liposomes are very unstable in plasma
due to desorption of ODNs from the liposomes and adsorption
onto serum proteins [12]. Cationic liposomes aggregate in blood
and the presence of a positive charge results in clearance by the
reticuloendothelial system within a few minutes of administra-
tion. Thus, only low amounts of ODNs are delivered to target
tissues such as tumors. Furthermore, cationic liposomes often
cause liver and inflammatory toxicities after systemic admin-
istration of cationic liposomes [13,14]. Therefore, cationic
liposomes are unlikely to work as a systemic carrier in clinical
applications.
CCL and SALP described by Stuart et al. [15,16] and Semple
et al. [17,18], respectively, were reported to overcome the
problems described above. Both these liposomal formulations
have high encapsulation efficiencies, good stability in blood,
long duration after intravenous administration and in vivo
activities, and, therefore, it is expected that these liposomes may
have clinical application. These liposomes have packed bilayers
comprised of cholesterol or lipids that have a high gel–liquid
crystal phase transition temperature. On the other hand, the
wrapped liposomes have loose bilayers comprised of EPCs,
which have low phase transition temperature. In general, factors
that lead to increased order in the lipid bilayer, such as increased
cholesterol content, acyl chain length or acyl chain saturation,
result in slower release properties [29]. Therefore, the wrapped
liposomes were expected to be more unstable and attacked by
high-density lipoproteins (HDL) more effectively than CCL and
SALP. However, in spite of the presence of unstable
membranes, after intravenous administration the wrapped
liposomes exhibited long half-lives that were comparable to
the duration of CCL and SALP. The presence of stable
membranes has the advantage that the liposomes and their
contents are likely to be delivered efficiently to target tissues but
the stable membranes may hinder delivery of liposomal
contents into the cytoplasm of target tissues [30]. It is feasible
that the wrapped liposomes could be more effective than either
CCL or SALP at delivering ODNs to the actual site of action
and thereby improve the therapeutic effectiveness of antisense
ODNs.
Unlike small molecule drugs such as doxorubicine, the
transport of macromolecules into cytoplasm appears to be
limited by permeation through liposomal membranes and cell
membranes. We wished to investigate whether (i) the wrapped
liposome technique could be applied to nucleic acids such as
ODNs, siRNAs and plasmids, (ii) wrapped liposomes would
deliver nucleic acids to target sites, and (iii) wrapped liposomes
would improve the therapeutic activity as compared to free
nucleic acids. Additional investigations were performed usingthe wrapped liposomes encapsulating a siRNA that inhibits
expression of Krüppel-like zinc-finger 5 (KLF5). KLF5 is a
transcription factor that is involved in the processes of
cardiovascular remodeling and angiogenesis. It was discovered
that wrapped liposomes encapsulating KLF5 siRNA prevented
tumor angiogenesis and progression and significantly inhibited
tumor growth when administered to mouse via the tail vein
(Yagi, N. et al., unpublished data). KLF5 siRNA alone did not
exhibit similar efficacy. This finding demonstrates the exciting
potential of using the wrapped liposomes to achieve improved
clinical effectiveness of siRNAs.
Moreover, similar methodology is likely to be applicable to
the formulation of polycationic drugs in the wrapped liposomes.
We believe that the use of wrapped liposomes will be applicable
to a wide variety of charged compounds, including peptides and
proteins. The problem of encapsulating proteins into liposomes
has been difficult to overcome [7] but we expect that it will be
possible to encapsulate proteins efficiently in the wrapped
liposomes.
In summary, we have developed novel liposomes, which we
have termed wrapped liposomes, that incorporate important
advantages of neutral and cationic liposomes. We believe that
the wrapped liposomes offer a safe and practical means of
formulating polyanionic and polycationic drugs that can
achieve suitable pharmacokinetic profiles thereby overcoming
many of the drawbacks associated with the clinical development
of these types of drug.
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